Jennifer M. Taylor, MD, MPH

Houston, Texas

Baylor College of Medicine

Jennifer M. Taylor, MD, MPH, is an associate professor of urology and a practicing urologist at Baylor College of Medicine in Houston, Texas where she also serves as the residency program director for urology. Additionally, Dr. Taylor practices at the Michael E. DeBakey VA Medical Center where she is the director of urologic oncology for the VA urology service. Dr. Taylor earned her MD from the University of Texas Medical School in Houston, where she also completed an internship and residency, and she completed a fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center in New York City. She also earned an MPH from the Harvard T.H. Chan School of Public Health in Boston.

Dr. Taylor is involved in clinical research in multiple genitourinary malignancies, with a focus on bladder cancer, as well as in research on medical education and physician wellness and resilience. Dr. Taylor is involved in the national medical community and is a member of the American Urological Association, the Society of Urologic Oncology, the Society of Women in Urology, and the American College of Surgeons. She has won numerous awards, including Baylor College of Medicine’s Norton Rose Fulbright Faculty Excellence Award for Teaching and Evaluation and the Women of Excellence Award.

Talks by Jennifer M. Taylor, MD, MPH

New Strategies for Post-Operative Pain Management

Posted by Jennifer M. Taylor, MD, MPH | Oct 2019

Jennifer M. Taylor, MD, MPH, discusses the factors that led to the current opioid epidemic and the consequences of excessive perioperative opioid prescribing. She then identifies concrete and evidence-based strategies to reduce opioid prescribing and use in particular surgical cases.

Bladder Cancer and Immunotherapy

Posted by Jennifer M. Taylor, MD, MPH | Dec 2018

Jennifer M. Taylor, MD, MPH, provides a brief overview of the basic scientific concepts of cancer cell suppression with checkpoint inhibitors. She also reviews the initial clinical trials for atezolizumab and pembrolizumab, larger trials for various immunotherapies for bladder cancer, toxicity reports, and ongoing research regarding these drugs in different combinations and disease states.

Second-line Bladder Cancer Therapies When First Line Treatments Fail

Posted by Jennifer M. Taylor, MD, MPH | Oct 2018

Jennifer M. Taylor, MD, MPH, discusses risk-stratification in non-muscle invasive bladder cancer (NMIBC), definitions of treatment failure in this setting, and indicated workup for suspected failure. She then reviews intravesical chemotherapy options under investigation in clinical trials for Bacillus Calmette–Guérin (BCG) unresponsive NMIBC.